The Cosmc connection to the Tn antigen in cancer

Cancer Biomarkers

Volumn 14, Issue 1, 2014, Pages 63-81

  Ju, Tongzhong ^a   Aryal, Rajindra P ^a   Kudelka, Matthew R ^a   Wang, Yingchun ^a   Cummings, Richard D ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

cancer; Cosmc; T synthase; Tn antigen

Indexed keywords

CHAPERONE; GLYCOPROTEIN; SYNTHETASE; T SYNTHASE; TN ANTIGEN; UNCLASSIFIED DRUG; POLYSACCHARIDE; TUMOR ANTIGEN;

ANTIGEN EXPRESSION; ARTICLE; BIOSYNTHESIS; CELL CLONING; COLORECTAL CANCER; EMBRYO; EMBRYO DEATH; ENDOPLASMIC RETICULUM; ENZYME GLYCOSYLATION; ENZYME PURIFICATION; EPIGENETICS; GENE TARGETING; GOLGI COMPLEX; HUMAN; METABOLIC REGULATION; MOUSE EMBRYO; NONHUMAN; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN DEGRADATION; PROTEIN HOMEOSTASIS; X CHROMOSOME; ANIMAL; CARBOHYDRATE ANALYSIS; GENETICS; GLYCOSYLATION; METABOLISM; MOUSE; NEOPLASM;

ANIMALS; ANTIGENS, TUMOR-ASSOCIATED, CARBOHYDRATE; CARBOHYDRATE SEQUENCE; GLYCOSYLATION; HUMANS; MICE; NEOPLASMS; POLYSACCHARIDES;

EID: 84901830981     PISSN: 15740153     EISSN: 18758592     Source Type: Journal    
DOI: 10.3233/CBM-130375     Document Type: Article

References (207)

1. Eheman C, Henley SJ, Ballard-Barbash R, Jacobs EJ, Schymura MJ, Noone AM, Pan L, Anderson RN, Fulton JE, Kohler BA, Jemal A, Ward E, Plescia M, Ries LA, Edwards BK. Annual Report to the Nation on the status of cancer, 1975-2008, featuring cancers associated with excess weight and lack of sufficient physical activity. Cancer. 2012; 118(9): 2338-66.
2. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011; 61(2): 69-90.
3. Hamilton SR. Molecular pathology. Mol Oncol. 2012; 6(2): 177-81.
4. Marusyk A, Almendro V, Polyak K. Intra-tumour heterogeneity: A looking glass for cancer? Nat Rev Cancer. 2012; 12(5): 323-34.
5. La Thangue NB, Kerr DJ. Predictive biomarkers: A paradigm shift towards personalized cancer medicine. Nat Rev Clin Oncol. 2011; 8(10): 587-96.
6. Hanahan D, Weinberg RA. Hallmarks of cancer: The next generation. Cell. 2011; 144(5): 646-74.
7. Almaraz RT, Tian Y, Bhattarcharya R, Tan E, Chen SH, Dallas MR, Chen L, Zhang Z, Zhang H, Konstantopoulos K, Yarema KJ. Metabolic flux increases glycoprotein sialylation: implications for cell adhesion and cancer metastasis. Mol Cell Proteomics. 2012; 11(7): M112 017558. PMCID: 3394959.
8. Hakomori SI, Cummings RD. Glycosylation effects on cancer development. Glycoconj J. 2012; 29(8-9): 565-6.
9. Liu YC, Yen HY, Chen CY, Chen CH, Cheng PF, Juan YH, Khoo KH, Yu CJ, Yang PC, Hsu TL, Wong CH. Sialylation and fucosylation of epidermal growth factor receptor suppress its dimerization and activation in lung cancer cells. Proc Natl Acad Sci U S A. 2011; 108(28): 11332-7. PMCID: 3136320.
10. Peracaula R, Barrabes S, Sarrats A, Rudd PM, de Llorens R. Altered glycosylation in tumours focused to cancer diagnosis. Dis Markers. 2008; 25(4-5): 207-18.
11. Kim EH, Misek DE. Glycoproteomics-based identification of cancer biomarkers. Int J Proteomics. 2011; 2011: 601937. PMCID: 3195811.
12. Meany DL, Chan DW. Aberrant glycosylation associated with enzymes as cancer biomarkers. Clin Proteomics. 2011; 8(1): 7. PMCID: 3170274.
13. Ju T, Otto VI, Cummings RD. The Tn antigen-structural simplicity and biological complexity. Angewandte Chemie. 2011; 50(8): 1770-91.
14. Dall'Olio F, Malagolini N, Trinchera M, Chiricolo M. Mechanisms of cancer-associated glycosylation changes. Front Biosci. 2012; 17: 670-99.
15. Ohtsubo K, Marth JD. Glycosylation in cellular mechanisms of health and disease. Cell. 2006; 126(5): 855-67.
16. Hollingsworth MA, Swanson BJ. Mucins in cancer: protection and control of the cell surface. Nat Rev Cancer. 2004; 4(1): 45-60.
17. Zhang H, Guo T, Li X, Datta A, Park JE, Yang J, Lim SK, Tam JP, Sze SK. Simultaneous characterization of glyco- and phosphoproteomes of mouse brain membrane proteome with electrostatic repulsion hydrophilic interaction chromatography. Mol Cell Proteomics. 2010; 9(4): 635-47. PMCID: 2860239.
18. Brockhausen I, Yang J, Dickinson N, Ogata S, Itzkowitz SH. Enzymatic basis for sialyl-Tn expression in human colon cancer cells. Glycoconj J. 1998; 15(6): 595-603.
19. Orntoft TF, Vestergaard EM. Clinical aspects of altered glycosylation of glycoproteins in cancer. Electrophoresis. 1999; 20(2): 362-71.
20. Brockhausen I. Mucin-type O-glycans in human colon and breast cancer: glycodynamics and functions. EMBO Rep. 2006; 7(6): 599-604. PMCID: 1479595.
21. Hakomori S. Tumor-associated carbohydrate antigens defining tumor malignancy: basis for development of anti-cancer vaccines. Adv Exp Med Biol. 2001; 491: 369-402.
22. Springer GF. T and Tn, general carcinoma autoantigens. Science. 1984; 224(4654): 1198-206.
23. Taylor-Papadimitriou J, Burchell J, Miles DW, Dalziel M. MUC1 and cancer. Biochim Biophys Acta. 1999; 1455(2-3): 301-13.
24. Rutledge EA, Enns CA. Cleavage of the transferrin receptor is influenced by the composition of the O-linked carbohydrate at position 104. J Cell Physiol. 1996; 168(2): 284-93.
25. Rutledge EA, Root BJ, Lucas JJ, Enns CA. Elimination of the O-linked glycosylation site at Thr 104 results in the generation of a soluble human-transferrin receptor. Blood. 1994; 83(2): 580-6.
26. Hayes GR, Enns CA, Lucas JJ. Identification of the O-linked glycosylation site of the human transferrin receptor. Glycobiology. 1992; 2(4): 355-9.
27. Do SI, Cummings RD. Presence of O-linked oligosaccharide on a threonine residue in the human transferrin receptor. Glycobiology. 1992; 2(4): 345-53.
28. Cummings RD, Kornfeld S, Schneider WJ, Hobgood KK, Tolleshaug H, Brown MS, Goldstein JL. Biosynthesis of Nand O-linked oligosaccharides of the low density lipoprotein receptor. J Biol Chem. 1983; 258(24): 15261-73.
29. Kingsley DM, Kozarsky KF, Hobbie L, Krieger M. Reversible defects in O-linked glycosylation and LDL receptor expression in a UDP-Gal/UDP-GalNAc 4-epimerase deficient mutant. Cell. 1986; 44(5): 749-59.
30. Kozarsky K, Kingsley D, Krieger M. Use of a mutant cell line to study the kinetics and function of O-linked glycosylation of low density lipoprotein receptors. Proc Natl Acad Sci U S A. 1988; 85(12): 4335-9.
31. Davis CG, Elhammer A, Russell DW, Schneider WJ, Kornfeld S, Brown MS, Goldstein JL. Deletion of clustered Olinked carbohydrates does not impair function of low density lipoprotein receptor in transfected fibroblasts. J Biol Chem. 1986; 261(6): 2828-38.
32. Liu W, Ramachandran V, Kang J, Kishimoto TK, Cummings RD, McEver RP. Identification of N-terminal residues on P-selectin glycoprotein ligand-1 required for binding to Pselectin. J Biol Chem. 1998; 273(12): 7078-87.
33. Wilkins PP, McEver RP, Cummings RD. Structures of the O-glycans on P-selectin glycoprotein ligand-1 from HL-60 cells. J Biol Chem. 1996; 271(31): 18732-42.
34. Leppanen A, Mehta P, Ouyang YB, Ju T, Helin J, Moore KL, van Die I, Canfield WM, McEver RP, Cummings RD. A novel glycosulfopeptide binds to P-selectin and inhibits leukocyte adhesion to P-selectin. J Biol Chem. 1999; 274(35): 24838-48.
35. Patton S, Gendler SJ, Spicer AP. The epithelial mucin, MUC1, of milk, mammary gland and other tissues. Biochim Biophys Acta. 1995; 1241(3): 407-23.
36. Gendler SJ. MUC1, the renaissance molecule. J Mammary Gland Biol Neoplasia. 2001; 6(3): 339-53.
37. Thornton DJ, Howard M, Khan N, Sheehan JK. Identification of two glycoforms of the MUC5B mucin in human respiratory mucus. Evidence for a cysteine-rich sequence repeated within the molecule. J Biol Chem. 1997; 272(14): 9561-6.
38. Silverman HS, Parry S, Sutton-Smith M, Burdick MD, Mc-Dermott K, Reid CJ, Batra SK, Morris HR, Hollingsworth MA, Dell A, Harris A. In vivo glycosylation of mucin tandem repeats. Glycobiology. 2001; 11(6): 459-71.
39. Yonezawa S, Sato E. Expression of mucin antigens in human cancers and its relationship with malignancy potential. Pathol Int. 1997; 47(12): 813-30.
40. Hansen JE, Lund O, Engelbrecht J, Bohr H, Nielsen JO. Prediction of O-glycosylation of mammalian pro teins: specificity patterns of UDP-GalNAc:polypeptide Nacetylgalactosaminyltransferase. Biochem J. 1995; 308 (Pt 3): 801-13. PMCID: 1136796.
41. Xia B, Royall JA, Damera G, Sachdev GP, Cummings RD. Altered O-glycosylation and sulfation of airway mucins associated with cystic fibrosis. Glycobiology. 2005; 15(8): 747-75.
42. Wang Y, Jobe SM, Ding X, Choo H, Archer D, Mi R, Ju T, Cummings RD. Platelet Biogenesis and Functions Require Correct Protein O-Glycosylation. Proc Natl Acad Sci U S A. 2012; 109(40): 16143-8.
43. Gill DJ, Clausen H, Bard F. Location, location, location: New insights into O-GalNAc protein glycosylation. Trends Cell Biol. 2011; 21(3): 149-58.
44. Tian E, Ten Hagen KG. Recent insights into the biological roles of mucin-type O-glycosylation. Glycoconj J. 2009; 26(3): 325-34.
45. Tarp MA, Clausen H. Mucin-type O-glycosylation and its potential use in drug and vaccine development. Biochim Biophys Acta. 2008; 1780(3): 546-63.
46. Schachter H, Brockhausen I. The Biosynthesis of Serine (Threonine)-N-acetylgalactosamine-linked Carbohydrate Moieties. In: Allen HJ, Kisailus EC, editors. Glycoconjugates: Composition, Structure and Function. New York: Marcel Dekker Inc., 1992, pp. 263-332.
47. Bennett EP, Mandel U, Clausen H, Gerken TA, Fritz TA, Tabak LA. Control of mucin-type O-glycosylation: a classification of the polypeptide GalNAc-transferase gene family. Glycobiology. 2012; 22(6): 736-56. PMCID: 3409716.
48. Tenno M, Saeki A, Kezdy FJ, Elhammer AP, Kurosaka A. The lectin domain of UDP-GalNAc: polypeptide N-acetylgalactosaminyltransferase 1 is involved in O-glycosylation of a polypeptide with multiple acceptor sites. J Biol Chem. 2002; 277(49): 47088-96.
49. Hassan H, Reis CA, Bennett EP, Mirgorodskaya E, Roepstorff P, Hollingsworth MA, Burchell J, Taylor-Papadimitriou J, Clausen H. The lectin domain of UDP-Nacetyl-D-galactosamine: polypeptide N- acetylgalactosaminyltransferase-T4 directs its glycopeptide specificities. J Biol Chem. 2000; 275(49): 38197-205.
50. Reepmaker J. The relation between polyagglutinability of erythrocytes in vivo and the Hubener-Thomsen-Friedenreich phenomenon. J Clin Pathol. 1952; 5(3): 266-70. PMCID: 1023599.
51. Uhlenbruck G. The Thomsen-Friedenreich (TF) receptor: An old history with new mystery. Immunol Commun. 1981; 10(3): 251-64.
52. Brockhausen I, Yang J, Lehotay M, Ogata S, Itzkowitz S. Pathways of mucin O-glycosylation in normal and malignant rat colonic epithelial cells reveal a mechanism for cancerassociated Sialyl-Tn antigen expression. Biol Chem. 2001; 382(2): 219-32.
53. Vavasseur F, Dole K, Yang J, Matta KL, Myerscough N, Corfield A, Paraskeva C, Brockhausen I. O-glycan biosynthesis in human colorectal adenoma cells during progression to cancer. Eur J Biochem. 1994; 222(2): 415-24.
54. An G, Wei B, Xia B, McDaniel JM, Ju T, Cummings RD, Braun J, Xia L. Increased susceptibility to colitis and colorectal tumors in mice lacking core 3-derived O-glycans. J Exp Med. 2007; 204(6): 1417-29.
55. Xia L, Ju T, Westmuckett A, An G, Ivanciu L, McDaniel JM, Lupu F, Cummings RD, McEver RP. Defective angiogenesis and fatal embryonic hemorrhage in mice lacking core 1- derived O-glycans. J Cell Biol. 2004; 164(3): 451-9.
56. Fu J, Gerhardt H, McDaniel JM, Xia B, Liu X, Ivanciu L, Ny A, Hermans K, Silasi-Mansat R, McGee S, Nye E, Ju T, Ramirez MI, Carmeliet P, Cummings RD, Lupu F, Xia L. Endothelial cell O-glycan deficiency causes blood/lymphatic misconnections and consequent fatty liver disease in mice. J Clin Invest. 2008; 118(11): 3725-37.
57. Fu J, Wei B, Wen T, Johansson ME, Liu X, Bradford E, Thomsson KA, McGee S, Mansour L, Tong M, McDaniel JM, Sferra TJ, Turner JR, Chen H, Hansson GC, Braun J, Xia L. Loss of intestinal core 1-derived O-glycans causes spontaneous colitis in mice. J Clin Invest. 2011; 121(4): 1657-66. PMCID: 3069788.
58. Rottger S, White J, Wandall HH, Olivo JC, Stark A, Bennett EP, Whitehouse C, Berger EG, Clausen H, Nilsson T. Localization of three human polypeptide GalNAc-transferases in HeLa cells suggests initiation of O-linked glycosylation throughout the Golgi apparatus. J Cell Sci. 1998; 111 (Pt 1): 45-60.
59. Gill DJ, Chia J, Senewiratne J, Bard F. Regulation of O-glycosylation through Golgi-to-ER relocation of initiation enzymes. J Cell Biol. 2010; 189(5): 843-58. PMCID: 2878949.
60. Brockhausen I, Moller G, Pollex-Kruger A, Rutz V, Paulsen H, Matta KL. Control of O-glycan synthesis: specificity and inhibition of O-glycan core 1 UDP-galactose:Nacetylgalactosamine-alpha-R beta 3-galactosyltransferase from rat liver. Biochem Cell Biol. 1992; 70(2): 99-108.
61. Brockhausen I, Moller G, Merz G, Adermann K, Paulsen H. Control of mucin synthesis: the peptide portion of synthetic O-glycopeptide substrates influences the activity of O-glycan core 1 UDPgalactose: N-acetyl-alphagalactosaminyl-R beta 3-galactosyltransferase. Biochemistry. 1990; 29(44): 10206-12.
62. Amado M, Almeida R, Carneiro F, Levery SB, Holmes EH, Nomoto M, Hollingsworth MA, Hassan H, Schwientek T, Nielsen PA, Bennett EP, Clausen H. A family of human beta3-galactosyltransferases. Characterization of four members of a UDP-galactose:beta-N-acetyl-glucosamine/betanacetyl-galactosamine beta-1,3-galactosyltransferase family. J Biol Chem. 1998; 273(21): 12770-8.
63. Kolbinger F, Streiff MB, Katopodis AG. Cloning of a human UDP-galactose: 2-acetamido-2-deoxy-D-glucose 3beta-galactosyltransferase catalyzing the formation of type 1 chains. J Biol Chem. 1998; 273(1): 433-40.
64. Ju T, Cummings RD, Canfield WM. Purification, characterization, and subunit structure of rat core 1 Beta1,3- galactosyltransferase. J Biol Chem. 2002; 277(1): 169-77.
65. Ju T, Brewer K, D'Souza A, Cummings RD, Canfield WM. Cloning and expression of human core 1 beta1, 3- galactosyltransferase. J Biol Chem. 2002; 277(1): 178-86.
66. Ju T, Cummings RD. A unique molecular chaperone Cosmc required for activity of the mammalian core 1 beta 3- galactosyltransferase. Proc Natl Acad Sci U S A. 2002; 99(26): 16613-8.
67. Piller V, Piller F, Fukuda M. Biosynthesis of truncated Oglycans in the T cell line Jurkat. Localization of O-glycan initiation. J Biol Chem. 1990; 265(16): 9264-71.
68. Schneider U, Schwenk HU, Bornkamm G. Characterization of EBV-genome negative "null" and "T" cell lines derived from children with acute lymphoblastic leukemia and leukemic transformed non-Hodgkin lymphoma. Int J Cancer. 1977; 19(5): 621-6.
69. Ju T, Aryal RP, Stowell CJ, Cummings RD. Regulation of protein O-glycosylation by the endoplasmic reticulum localized molecular chaperone Cosmc. J Cell Biol. 2008; 182(3): 531-42.
70. Narimatsu Y, Ikehara Y, Iwasaki H, Nonomura C, Sato T, Nakanishi H, Narimatsu H. Immunocytochemical analysis for intracellular dynamics of C1GalT associated with molecular chaperone, Cosmc. Biochem Biophys Res Commun. 2008; 366(1): 199-205.
71. Sun Q, Ju T, Cummings RD. The transmembrane domain of the molecular chaperone Cosmc directs its localization to the endoplasmic reticulum. J Biol Chem. 2011; 286(13): 11529-42. PMCID: 3064207.
72. Kudo T, Iwai T, Kubota T, Iwasaki H, Takayma Y, Hiruma T, Inaba N, Zhang Y, Gotoh M, Togayachi A, Narimatsu H. Molecular cloning and characterization of a novel UDPGal: GalNAc (alpha) peptide beta 1,3-galactosyltransferase (C1Gal-T2), an enzyme synthesizing a core 1 structure of O-glycan. J Biol Chem. 2002; 277(49): 47724-31.
73. Ju T, Zheng Q, Cummings RD. Identification of core 1 Oglycan T-synthase from Caenorhabditis elegans. Glycobiology. 2006; 16(10): 947-58.
74. Muller R, Hulsmeier AJ, Altmann F, Ten Hagen K, Tiemeyer M, Hennet T. Characterization of mucin-type core-1 beta1-3 galactosyltransferase homologous enzymes in Drosophila melanogaster. Febs J. 2005; 272(17): 4295-305.
75. Aryal RP, Ju T, Cummings RD. Tight complex formation between Cosmc chaperone and its specific client non-native T-synthase leads to enzyme activity and client-driven dissociation. J Biol Chem. 2012; 287(19): 15317-29. PMCID: 3346102.
76. Aryal RP, Ju T, Cummings RD. The endoplasmic reticulum chaperone Cosmc directly promotes in vitro folding of Tsynthase. J Biol Chem. 2010; 285(4): 2456-62.
77. Wang Y, Ju T, Ding X, Xia B, Wang W, Xia L, He M, Cummings RD. Cosmc is an Essential Chaperone for Correct Protein O-Glycosylation. Proc Natl Acad Sci U S A. 2010, In Press.
78. Berger EG. Tn-syndrome. Biochim Biophys Acta. 1999; 1455(2-3): 255-68.
79. Cartron JP, Nurden AT. Galactosyltransferase and membrane glycoprotein abnormality in human platelets from Tnsyndrome donors. Nature. 1979; 282(5739): 621-3.
80. Cartron JP, Cartron J, Andreu G, Salmon C, Bird GW. Selective deficiency of 3-beta-d-galactosyltransferase (Ttransferase) in Tn-polyagglutinable erythrocytes. Lancet. 1978; 1(8069): 856-7.
81. Felner KM, Dinter A, Cartron JP, Berger EG. Repressed beta-1,3-galactosyltransferase in the Tn syndrome. Biochim Biophys Acta. 1998; 1406(1): 115-25.
82. Ju T, Cummings RD. Protein glycosylation: chaperone mutation in Tn syndrome. Nature. 2005; 437(7063): 1252.
83. Crew VK, Singleton BK, Green C, Parsons SF, Daniels G, Anstee DJ. New mutations in C1GALT1C1 in individuals with Tn positive phenotype. Br J Haematol. 2008; 142(4): 657-67.
84. Ju T, Otto VI, Cummings RD. The Tn antigen-structural simplicity and biological complexity. Angew Chem Int Ed Engl. 2011; 50(8): 1770-91.
85. Vainchenker W, Vinci G, Testa U, Henri A, Tabilio A, Fache MP, Rochant H, Cartron JP. Presence of the Tn antigen on hematopoietic progenitors from patients with the Tn syndrome. J Clin Invest. 1985; 75(2): 541-6. PMCID: 423529.
86. Moreau R, Dausset J, Bernard J, Moullec J. [Acquired hemolytic anemia with polyagglutinability of erythrocytes by a new factor present in normal blood.]. Bull Mem Soc Med Hop Paris. 1957; 73(20-21): 569-87.
87. Friedenreich V. The Thomsen Hemagglutination Phenomenon: Production of a Specific Receptor Quality in Red Corpuscles by Bacterial Activity (Dissertation Thesis). Copenhagen: Levin and Munksgaard, 1930.
88. Dausset J, Moullec J, Bernard J. Acquired hemolytic anemia with polyagglutinability of red blood cells due to a new factor present in normal human serum (Anti-Tn). Blood. 1959; 14: 1079-93.
89. Dahr W, Uhlenbruck G, Bird GW. Cryptic A-like receptor sites in human erythrocyte glycoproteins: proposed nature of Tn-antigen. Vox Sang. 1974; 27(1): 29-42.
90. Dahr W, Uhlenbruck G, Gunson HH, Van Der Hart M. Molecular basis of Tn-polyagglutinability. Vox Sang. 1975; 29(1): 36-50.
91. Muroi K, Suda T, Nakamura M, Okada S, Nojiri H, Amemiya Y, Miura Y, Hakomori S. Expression of sialosyl-Tn in colony-forming unit-erythroid, erythroblasts, B cells, and a subset of CD4+ cells. Blood. 1994; 83(1): 84-91.
92. Kawano-Yamamoto C, Muroi K, Nagatsuka Y, Higuchi M, Kikuchi S, Nagai T, Hakomori SI, Ozawa K. Establishment and characterization of a new erythroblastic leukemia cell line, EEB: phosphatidylglucoside-mediated erythroid differentiation and apoptosis. Leuk Res. 2006; 30(7): 829-39.
93. Jass JR, Allison LM, Edgar S. Monoclonal antibody TKH2 to the cancer-associated epitope sialosyl Tn shows crossreactivity with variants of normal colorectal goblet cell mucin. Pathology. 1994; 26(4): 418-22.
94. Cao Y, Merling A, Karsten U, Goletz S, Punzel M, Kraft R, Butschak G, Schwartz-Albiez R. Expression of CD175 (Tn), CD175s (sialosyl-Tn) and CD176 (Thomsen-Friedenreich antigen) on malignant human hematopoietic cells. Int J Cancer. 2008; 123(1): 89-99.
95. Loaiza-Bonilla A, Horowitz D, Sheela S, Baral A, Tinoco G, Kyriakopoulos C. Persistent Tn polyagglutination syndrome during febrile neutropenia: A case report and review of the literature. J Med Case Rep. 2011; 5: 8. PMCID: 3025968.
96. Springer GF, Desai PR, Banatwala I. Blood group MN antigens and precursors in normal and malignant human breast glandular tissue. J Natl Cancer Inst. 1975; 54(2): 335-9.
97. Springer GF, Desai PR, Banatwala I. Blood group MN specific substances and precursors in normal and malignant human breast tissues. Naturwissenschaften. 1974; 61(10): 457-8.
98. Springer GF, Taylor CR, Howard DR, Tegtmeyer H, Desai PR, Murthy SM, Felder B, Scanlon EF. Tn, a carcinomaassociated antigen, reacts with anti-Tn of normal human sera. Cancer. 1985; 55(3): 561-9.
99. Kjeldsen T, Clausen H, Hirohashi S, Ogawa T, Iijima H, Hakomori S. Preparation and characterization of monoclonal antibodies directed to the tumor-associated O-linked sialosyl-2-6 alpha-N-acetylgalactosaminyl (sialosyl-Tn) epitope. Cancer research. 1988; 48(8): 2214-20.
100. Itzkowitz SH, Yuan M, Montgomery CK, Kjeldsen T, Takahashi HK, Bigbee WL, Kim YS. Expression of Tn, sialosyl-Tn, and T antigens in human colon cancer. Cancer Res. 1989; 49(1): 197-204.
101. Tsuchiya A, Kanno M, Kawaguchi T, Endo Y, Zhang GJ, Ohtake T, Kimijima II. Prognostic Relevance of Tn Expression in Breast Cancer. Breast Cancer. 1999; 6(3): 175-80.
102. Inoue M, Ton SM, Ogawa H, Tanizawa O. Expression of Tn and sialyl-Tn antigens in tumor tissues of the ovary. Am J Clin Pathol. 1991; 96(6): 711-6.
103. Terasawa K, Furumoto H, Kamada M, Aono T. Expression of Tn and sialyl-Tn antigens in the neoplastic transformation of uterine cervical epithelial cells. Cancer Res. 1996; 56(9): 2229-32.
104. Itzkowitz S, Kjeldsen T, Friera A, Hakomori S, Yang US, Kim YS. Expression of Tn, sialosyl Tn, and T antigens in human pancreas. Gastroenterology. 1991; 100(6): 1691-700.
105. Springer GF. Immunoreactive T and Tn epitopes in cancer diagnosis, prognosis, and immunotherapy. J Mol Med. 1997; 75(8): 594-602.
106. Taylor-Papadimitriou J, Epenetos AA. Exploiting altered glycosylation patterns in cancer: progress and challenges in diagnosis and therapy. Trends Biotechnol. 1994; 12(6): 227-33.
107. Konska G, Guerry M, Caldefie-Chezet F, De Latour M, Guillot J. Study of the expression of Tn antigen in different types of human breast cancer cells using VVA-B4 lectin. Oncol Rep. 2006; 15(2): 305-10.
108. Julien S, Adriaenssens E, Ottenberg K, Furlan A, Courtand G, Vercoutter-Edouart AS, Hanisch FG, Delannoy P, Le Bourhis X. ST6GalNAc I expression in MDA-MB-231 breast cancer cells greatly modifies their O-glycosylation pattern and enhances their tumourigenicity. Glycobiology. 2006; 16(1): 54-64.
109. Kobayashi H, Terao T, Kawashima Y. Clinical evaluation of circulating serum sialyl Tn antigen levels in patients with epithelial ovarian cancer. J Clin Oncol. 1991; 9(6): 983-7.
110. Kobayashi H, Terao T, Kawashima Y. Serum sialyl Tn as an independent predictor of poor prognosis in patients with epithelial ovarian cancer. J Clin Oncol. 1992; 10(1): 95-101.
111. Akita K, Yoshida S, Ikehara Y, Shirakawa S, Toda M, Inoue M, Kitawaki J, Nakanishi H, Narimatsu H, Nakada H. Different levels of sialyl-Tn antigen expressed on MUC16 in patients with endometriosis and ovarian cancer. Int J Gynecol Cancer. 2012; 22(4): 531-8.
112. Marcos NT, Bennett EP, Gomes J, Magalhaes A, Gomes C, David L, Dar I, Jeanneau C, DeFrees S, Krustrup D, Vogel LK, Kure EH, Burchell J, Taylor-Papadimitriou J, Clausen H, Mandel U, Reis CA. ST6GalNAc-I controls expression of sialyl-Tn antigen in gastrointestinal tissues. Front Biosci (Elite Ed). 2011; 3: 1443-55.
113. Orntoft TF, Harving N, Langkilde NC. O-linked mucin-type glycoproteins in normal and malignant colon mucosa: lack of T-antigen expression and accumulation of Tn and sialosyl-Tn antigens in carcinomas. Int J Cancer. 1990; 45(4): 666-72.
114. Schumacher U, Higgs D, Loizidou M, Pickering R, Leathem A, Taylor I. Helix pomatia agglutinin binding is a useful prognostic indicator in colorectal carcinoma. Cancer. 1994; 74(12): 3104-7.
115. Mitchell BS, Schumacher U. The use of the lectin Helix pomatia agglutinin (HPA) as a prognostic indicator and as a tool in cancer research. Histol Histopathol. 1999; 14(1): 217-26.
116. Imada T, Rino Y, Hatori S, Takahashi M, Amano T, Kondo J, Suda T. Sialyl Tn antigen expression is associated with the prognosis of patients with advanced colorectal cancer. Hepatogastroenterology. 1999; 46(25): 208-14.
117. Wargovich MJ, Chang P, Velasco M, Sinicrope F, Eisenbrodt E, Sellin J. Expression of cellular adhesion proteins and abnormal glycoproteins in human aberrant crypt foci. Appl Immunohistochem Mol Morphol. 2004; 12(4): 350-5.
118. Yuan M. [The expression of Tn and S-Tn antigens in cancer and pre-malignant lesion of colorectal tissues by enzyme immunohistochemical method]. Zhonghua Bing Li Xue Za Zhi. 1989; 18(3): 211-3.
119. Itzkowitz SH, Bloom EJ, Lau TS, Kim YS. Mucin associated Tn and sialosyl-Tn antigen expression in colorectal polyps. Gut. 1992; 33(4): 518-23.
120. Berriel E, Hill M, Barcia JJ, Ubillos L, Gonzalez M, Detjen G, Rondan M, Navarrete H, Osinaga E. Simple mucintype cancer associated antigens are pre-cancerous biomarkers during 1,2-dimethylhydrazine-induced rat colon carcinogenesis. Oncol Rep. 2005; 14(1): 219-27.
121. Senapati S, Sharma P, Bafna S, Roy HK, Batra SK. The MUC gene family: their role in the diagnosis and prognosis of gastric cancer. Histol Histopathol. 2008; 23(12): 1541-52.
122. Byrd JC, Bresalier RS. Mucins and mucin binding proteins in colorectal cancer. Cancer Metastasis Rev. 2004; 23(1-2): 77-99.
123. Van der Sluis M, De Koning BA, De Bruijn AC, Velcich A, Meijerink JP, Van Goudoever JB, Buller HA, Dekker J, Van Seuningen I, Renes IB, Einerhand AW. Muc2-deficient mice spontaneously develop colitis, indicating that MUC2 is critical for colonic protection. Gastroenterology. 2006; 131(1): 117-29.
124. Velcich A, Yang W, Heyer J, Fragale A, Nicholas C, Viani S, Kucherlapati R, Lipkin M, Yang K, Augenlicht L. Colorectal cancer in mice genetically deficient in the mucin Muc2. Science. 2002; 295(5560): 1726-9.
125. Yang K, Popova NV, Yang WC, Lozonschi I, Tadesse S, Kent S, Bancroft L, Matise I, Cormier RT, Scherer SJ, Edelmann W, Lipkin M, Augenlicht L, Velcich A. Interaction of Muc2 and Apc on Wnt signaling and in intestinal tumorigenesis: potential role of chronic inflammation. Cancer Res. 2008; 68(18): 7313-22.
126. Yu LG, Andrews N, Zhao Q, McKean D, Williams JF, Connor LJ, Gerasimenko OV, Hilkens J, Hirabayashi J, Kasai K, Rhodes JM. Galectin-3 interaction with Thomsen-Friedenreich disaccharide on cancer-associated MUC1 causes increased cancer cell endothelial adhesion. J Biol Chem. 2007; 282(1): 773-81.
127. Wagner KW, Punnoose EA, Januario T, Lawrence DA, Pitti RM, Lancaster K, Lee D, von Goetz M, Yee SF, Totpal K, Huw L, Katta V, Cavet G, Hymowitz SG, Amler L, Ashkenazi A. Death-receptor O-glycosylation controls tumor-cell sensitivity to the proapoptotic ligand Apo2L/TRAIL. Nat Med. 2007; 13(9): 1070-7.
128. Kim LC, Song L, Haura EB. Src kinases as therapeutic targets for cancer. Nat Rev Clin Oncol. 2009; 6(10): 587-95.
129. Clarke E, Green RC, Green JS, Mahoney K, Parfrey PS, Younghusband HB, Woods MO. Inherited deleterious variants in GALNT12 are associated with CRC susceptibility. Hum Mutat. 2012; 33(7): 1056-8.
130. Guo JM, Chen HL, Wang GM, Zhang YK, Narimatsu H. Expression of UDP-GalNAc: polypeptide N-acetylgalactosaminyltransferase- 12 in gastric and colonic cancer cell lines and in human colorectal cancer. Oncology. 2004; 67(3-4): 271-6.
131. Guda K, Moinova H, He J, Jamison O, Ravi L, Natale L, Lutterbaugh J, Lawrence E, Lewis S, Willson JK, Lowe JB, Wiesner GL, Parmigiani G, Barnholtz-Sloan J, Dawson DW, Velculescu VE, Kinzler KW, Papadopoulos N, Vogelstein B, Willis J, Gerken TA, Markowitz SD. Inactivating germ-line and somatic mutations in polypeptide Nacetylgalactosaminyltransferase 12 in human colon cancers. Proc Natl Acad Sci U S A. 2009; 106(31): 12921-5. PMCID: 2722285.
132. Brooks SA, Carter TM, Bennett EP, Clausen H, Mandel U. Immunolocalisation of members of the polypeptide Nacetylgalactosaminyl transferase (ppGalNAc-T) family is consistent with biologically relevant altered cell surface glycosylation in breast cancer. Acta Histochem. 2007; 109(4): 273-84.
133. Scott KL, Chin L. Signaling from the Golgi: mechanisms and models for Golgi phosphoprotein 3-mediated oncogenesis. Clin Cancer Res. 2010; 16(8): 2229-34. PMCID: 2855764.
134. Kellokumpu S, Sormunen R, Kellokumpu I. Abnormal glycosylation and altered Golgi structure in colorectal cancer: dependence on intra-Golgi pH. FEBS Lett. 2002; 516(1-3): 217-24.
135. Hassinen A, Pujol FM, Kokkonen N, Pieters C, Kihlstrom M, Korhonen K, Kellokumpu S. Functional organization of Golgi N- and O-glycosylation pathways involves pHdependent complex formation that is impaired in cancer cells. J Biol Chem. 2011; 286(44): 38329-40. PMCID: 3207439.
136. Ju T, Lanneau GS, Gautam T, Wang Y, Xia B, Stowell SR, Willard MT, Wang W, Xia JY, Zuna RE, Laszik Z, Benbrook DM, Hanigan MH, Cummings RD. Human tumor antigens Tn and sialyl Tn arise from mutations in Cosmc. Cancer Res. 2008; 68(6): 1636-46.
137. Schietinger A, Philip M, Yoshida BA, Azadi P, Liu H, Meredith SC, Schreiber H. A mutant chaperone converts a wild-type protein into a tumor-specific antigen. Science. 2006; 314(5797): 304-8.
138. Thurnher M, Rusconi S, Berger EG. Persistent repression of a functional allele can be responsible for galactosyltransferase deficiency in Tn syndrome. J Clin Invest. 1993; 91(5): 2103-10.
139. Yamada K, Kobayashi N, Ikeda T, Suzuki Y, Tsuge T, Horikoshi S, Emancipator SN, Tomino Y. Down-regulation of core 1 {beta}1,3- galactosyltransferase and Cosmc by Th2 cytokine alters O-glycosylation of IgA1. Nephrol Dial Transplant, 2010.
140. Peng RQ, Wan HY, Li HF, Liu M, Li X, Tang H. MicroRNA- 214 suppresses growth and invasiveness of cervical cancer cells by targeting UDP-N-acetyl-alpha-D-galactosamine: polypeptide N- acetylgalactosaminyltransferase 7. J Biol Chem. 2012; 287(17): 14301-9. PMCID: 3340176.
141. Matsumoto Y, Zhang Q, Akita K, Nakada H, Hamamura K, Tokuda N, Tsuchida A, Matsubara T, Hori T, Okajima T, Furukawa K, Urano T. pp-GalNAc-T13 induces high metastatic potential of murine Lewis lung cancer by generating trimeric Tn antigen. Biochem Biophys Res Commun. 2012; 419(1): 7-13.
142. Wu YM, Liu CH, Hu RH, Huang MJ, Lee JJ, Chen CH, Huang J, Lai HS, Lee PH, Hsu WM, Huang HC, Huang MC. Mucin glycosylating enzyme GALNT2 regulates the malignant character of hepatocellular carcinoma by modifying the EGF receptor. Cancer Res. 2011; 71(23): 7270-9.
143. Liu J, Yang L, Jin M, Xu L, Wu S. regulation of the invasion and metastasis of human glioma cells by polypeptide Nacetylgalactosaminyltransferase 2. Mol Med Report. 2011; 4(6): 1299-305.
144. Taniuchi K, Cerny RL, Tanouchi A, Kohno K, Kotani N, Honke K, Saibara T, Hollingsworth MA. Overexpression of GalNAc-transferase GalNAc-T3 promotes pancreatic cancer cell growth. Oncogene. 2011; 30(49): 4843-54. PMCID: 3373266.
145. Li Z, Yamada S, Inenaga S, Imamura T, Wu Y, Wang KY, Shimajiri S, Nakano R, Izumi H, Kohno K, Sasaguri Y. Polypeptide N-acetylgalactosaminyltransferase 6 expression in pancreatic cancer is an independent prognostic factor indicating better overall survival. Br J Cancer. 2011; 104(12): 1882-9. PMCID: 3111199.
146. Park JH, Katagiri T, Chung S, Kijima K, Nakamura Y. Polypeptide N-acetylgalactosaminyltransferase 6 disrupts mammary acinar morphogenesis through O-glycosylation of fibronectin. Neoplasia. 2011; 13(4): 320-6. PMCID: 3071080.
147. Ichikawa S, Baujat G, Seyahi A, Garoufali AG, Imel EA, Padgett LR, Austin AM, Sorenson AH, Pejin Z, Topouchian V, Quartier P, Cormier-Daire V, Dechaux M, Malandrinou F, Singhellakis PN, Le Merrer M, Econs MJ. Clinical variability of familial tumoral calcinosis caused by novel GALNT3 mutations. Am J Med Genet A. 2010; 152A(4): 896-903. PMCID: 3392654.
148. Wu C, Guo X, Wang W, Wang Y, Shan Y, Zhang B, Song W, Ma S, Ge J, Deng H, Zhu M. N-Acetylgalactosaminyltransferase- 14 as a potential biomarker for breast cancer by immunohistochemistry. BMC Cancer. 2010; 10: 123. PMCID: 2873381.
149. Park JH, Nishidate T, Kijima K, Ohashi T, Takegawa K, Fujikane T, Hirata K, Nakamura Y, Katagiri T. Critical roles of mucin 1 glycosylation by transactivated polypeptide Nacetylgalactosaminyltransferase 6 in mammary carcinogenesis. Cancer Res. 2010; 70(7): 2759-69.
150. Phelan CM, Tsai YY, Goode EL, Vierkant RA, Fridley BL, Beesley J, Chen XQ, Webb PM, Chanock S, Cramer DW, Moysich K, Edwards RP, Chang-Claude J, Garcia-Closas M, Yang H, Wang-Gohrke S, Hein R, Green AC, Lissowska J, Carney ME, Lurie G, Wilkens LR, Ness RB, Pearce CL, Wu AH, Van Den Berg DJ, Stram DO, Terry KL, Whiteman DC, Whittemore AS, DiCioccio RA, McGuire V, Doherty JA, Rossing MA, Anton-Culver H, Ziogas A, Hogdall C, Hogdall E, Kruger Kjaer S, Blaakaer J, Quaye L, Ramus SJ, Jacobs I, Song H, Pharoah PD, Iversen ES, Marks JR, Pike MC, Gayther SA, Cunningham JM, Goodman MT, Schildkraut JM, Chenevix-Trench G, Berchuck A, Sellers TA. Polymorphism in the GALNT1 gene and epithelial ovarian cancer in non-Hispanic white women: the Ovarian Cancer Association Consortium. Cancer Epidemiol Biomarkers Prev. 2010; 19(2): 600-4. PMCID: 2880167.
151. Kato K, Takeuchi H, Kanoh A, Miyahara N, Nemoto-Sasaki Y, Morimoto-Tomita
152. Rajpert-De Meyts E, Poll SN, Goukasian I, Jeanneau C, Herlihy AS, Bennett EP, Skakkebaek NE, Clausen H, Giwercman A, Mandel U. Changes in the profile of simple mucintype O-glycans and polypeptide GalNAc-transferases in human testis and testicular neoplasms are associated with germ cell maturation and tumour differentiation. Virchows Arch. 2007; 451(4): 805-14.
153. Freire T, Berois N, Sonora C, Varangot M, Barrios E, Osinaga E. UDP-N-acetyl-D-galactosamine:polypeptide Nacetylgalactosaminyltransferase 6 (ppGalNAc-T6) mRNA as a potential new marker for detection of bone marrowdisseminated breast cancer cells. Int J Cancer. 2006; 119(6): 1383-8.
154. Berois N, Mazal D, Ubillos L, Trajtenberg F, Nicolas A, Sastre-Garau X, Magdelenat H, Osinaga E. UDP-N-acetyl-D-galactosamine: polypeptide N-acetylgalactosaminyltransferase- 6 as a new immunohistochemical breast cancer marker. J Histochem Cytochem. 2006; 54(3): 317-28.
155. Yamamoto S, Nakamori S, Tsujie M, Takahashi Y, Nagano H, Dono K, Umeshita K, Sakon M, Tomita Y, Hoshida Y, Aozasa K, Kohno K, Monden M. Expression of uridine diphosphate N-acetyl-alpha-D-galactosamine: polypeptide N-acetylgalactosaminyl transferase 3 in adenocarcinoma of the pancreas. Pathobiology. 2004; 71(1): 12-8.
156. Shibao K, Izumi H, Nakayama Y, Ohta R, Nagata N, Nomoto M, Matsuo K, Yamada Y, Kitazato K, Itoh H, Kohno K. Expression of UDP-N-acetyl-alpha-D- galactosaminepolypeptide galNAc N-acetylgalactosaminyl transferase-3 in relation to differentiation and prognosis in patients with colorectal carcinoma. Cancer. 2002; 94(7): 1939-46.
157. Kohsaki T, Nishimori I, Nakayama H, Miyazaki E, Enzan H, Nomoto M, Hollingsworth MA, Onishi S. Expression of UDP-GalNAc: polypeptide N-acetylgalactosaminyltransferase isozymes T1 and T2 in human colorectal cancer. J Gastroenterol. 2000; 35(11): 840-8.
158. Kabuss R, Ashikov A, Oelmann S, Gerardy-Schahn R, Bakker H. Endoplasmic reticulum retention of the large splice variant of the UDP-galactose transporter is caused by a dilysine motif. Glycobiology. 2005; 15(10): 905-11.
159. Rivinoja A, Hassinen A, Kokkonen N, Kauppila A, Kellokumpu S. Elevated Golgi pH impairs terminal Nglycosylation by inducing mislocalization of Golgi glycosyltransferases. J Cell Physiol. 2009; 220(1): 144-54.
160. Hassinen A, Rivinoja A, Kauppila A, Kellokumpu S. Golgi N-glycosyltransferases form both homo- and heterodimeric enzyme complexes in live cells. J Biol Chem. 2010; 285(23): 17771-7. PMCID: 2878541.
161. Opat AS, Houghton F, Gleeson PA. Medial Golgi but not late Golgi glycosyltransferases exist as high molecular weight complexes. Role of luminal domain in complex formation and localization. J Biol Chem. 2000; 275(16): 11836-45.
162. Sewell R, Backstrom M, Dalziel M, Gschmeissner S, Karlsson H, Noll T, Gatgens J, Clausen H, Hansson GC, Burchell J, Taylor-Papadimitriou J. The ST6GalNAc-I sialyltransferase localizes throughout the Golgi and is responsible for the synthesis of the tumor-associated sialyl-Tn O-glycan in human breast cancer. J Biol Chem. 2006; 281(6): 3586-94.
163. Vazquez-Martin C, Cuevas E, Gil-Martin E, Fernandez-Briera A. Correlation analysis between tumor-associated antigen sialyl-Tn expression and ST6GalNAc I activity in human colon adenocarcinoma. Oncology. 2004; 67(2): 159-65.
164. Julien S, Krzewinski-Recchi MA, Harduin-Lepers A, Gouyer V, Huet G, Le Bourhis X, Delannoy P. Expression of sialyl-Tn antigen in breast cancer cells transfected with the human CMP-Neu5Ac: GalNAc alpha2,6-sialyltransferase (ST6GalNac I) cDNA. Glycoconj J. 2001; 18(11-12): 883-93.
165. Marcos NT, Cruz A, Silva F, Almeida R, David L, Mandel U, Clausen H, Von Mensdorff-Pouilly S, Reis CA. Polypeptide GalNAc-transferases, ST6GalNAc-transferase I, and ST3Gal-transferase I expression in gastric carcinoma cell lines. J Histochem Cytochem. 2003; 51(6): 761-71.
166. Ikehara Y, Kojima N, Kurosawa N, Kudo T, Kono M, Nishihara S, Issiki S, Morozumi K, Itzkowitz S, Tsuda T, Nishimura SI, Tsuji S, Narimatsu H. Cloning and expression of a human gene encoding an N-acetylgalactosaminealpha2, 6-sialyltransferase (ST6GalNAc I): A candidate for synthesis of cancer-associated sialyl-Tn antigens. Glycobiology. 1999; 9(11): 1213-24.
167. Koike T, Kimura N, Miyazaki K, Yabuta T, Kumamoto K, Takenoshita S, Chen J, Kobayashi M, Hosokawa M, Taniguchi A, Kojima T, Ishida N, Kawakita M, Yamamoto H, Takematsu H, Suzuki A, Kozutsumi Y, Kannagi R. Hypoxia induces adhesion molecules on cancer cells: A missing link between Warburg effect and induction of selectin-ligand carbohydrates. Proc Natl Acad Sci U S A. 2004; 101(21): 8132-7.
168. Kumamoto K, Goto Y, Sekikawa K, Takenoshita S, Ishida N, Kawakita M, Kannagi R. Increased expression of UDPgalactose transporter messenger RNA in human colon cancer tissues and its implication in synthesis of Thomsen-Friedenreich antigen and sialyl Lewis A/X determinants. Cancer Res. 2001; 61(11): 4620-7.
169. Kiyohara M, Nakatomi T, Kurihara S, Fushinobu S, Suzuki H, Tanaka T, Shoda S, Kitaoka M, Katayama T, Yamamoto K, Ashida H. alpha-N- acetylgalactosaminidase from infantassociated bifidobacteria belonging to novel glycoside hydrolase family 129 is implicated in alternative mucin degradation pathway. J Biol Chem. 2012; 287(1): 693-700. PMCID: 3249124.
170. Kjeldsen T, Hakomori S, Springer GF, Desai P, Harris T, Clausen H. Coexpression of sialosyl-Tn (NeuAc alpha 2-6GalNAc alpha 1-O-Ser/Thr) and Tn (GalNAc alpha 1-OSer/Thr) blood group antigens on Tn erythrocytes. Vox Sang. 1989; 57(1): 81-7.
171. Avichezer D, Springer GF, Schechter B, Arnon R. Immunoreactivities of polyclonal and monoclonal anti-T and anti-Tn antibodies with human carcinoma cells, grown in vitro and in a xenograft model. Int J Cancer. 1997; 72(1): 119-27.
172. Hirohashi S, Clausen H, Yamada T, Shimosato Y, Hakomori S. Blood group A cross-reacting epitope defined by monoclonal antibodies NCC-LU-35 and -81 expressed in cancer of blood group O or B individuals: its identification as Tn antigen. Proc Natl Acad Sci U S A. 1985; 82(20): 7039-43. PMCID: 391305.
173. Numata Y, Nakada H, Fukui S, Kitagawa H, Ozaki K, Inoue M, Kawasaki T, Funakoshi I, Yamashina I. A monoclonal antibody directed to Tn antigen. Biochem Biophys Res Commun. 1990; 170(3): 981-5.
174. Takahashi HK, Metoki R, Hakomori S. Immunoglobulin G3 monoclonal antibody directed to Tn antigen (tumorassociated alpha-N-acetylgalactosaminyl epitope) that does not cross-react with blood group A antigen. Cancer Res. 1988; 48(15): 4361-7.
175. Li Q, Anver MR, Butcher DO, Gildersleeve JC. Resolving conflicting data on expression of the Tn antigen and implications for clinical trials with cancer vaccines. Mol Cancer Ther. 2009; 8(4): 971-9. PMCID: 2752371.
176. Thurnher M, Wagner E, Clausen H, Mechtler K, Rusconi S, Dinter A, Birnstiel ML, Berger EG, Cotten M. Carbohydrate receptor-mediated gene transfer to human T leukaemic cells. Glycobiology. 1994; 4(4): 429-35.
177. Borgert A, Heimburg-Molinaro J, Song X, Lasanajak Y, Ju T, Liu M, Thompson P, Ragupathi G, Barany G, Smith DF, Cummings RD, Live D. Deciphering structural elements of mucin glycoprotein recognition. ACS Chem Biol. 2012; 7(6): 1031-9.
178. Zou P, Povoski SP, Hall NC, Carlton MM, Hinkle GH, Xu RX, Mojzisik CM, Johnson MA, Knopp MV, Martin EW, Jr., Sun D. 124I-HuCC49deltaCH2 for TAG-72 antigen-directed positron emission tomography (PET) imaging of LS174T colon adenocarcinoma tumor implants in xenograft mice: preliminary results. World J Surg Oncol. 2010; 8: 65. PMCID: 2924340.
179. Morita N, Yajima Y, Asanuma H, Nakada H, Fujita-Yamaguchi Y. Inhibition of cancer cell growth by anti-Tn monoclonal antibody MLS128. Biosci Trends. 2009; 3(1): 32-7.
180. Kubota T, Matsushita T, Niwa R, Kumagai I, Nakamura K. Novel anti-Tn single-chain Fv-Fc fusion proteins derived from immunized phage library and antibody Fc domain. Anticancer Res. 2010; 30(9): 3397-405.
181. Ando H, Matsushita T, Wakitani M, Sato T, Kodama-Nishida S, Shibata K, Shitara K, Ohta S. Mouse-human chimeric anti-Tn IgG1 induced anti-tumor activity against Jurkat cells in vitro and in vivo. Biological and pharmaceutical bulletin. 2008; 31(9): 1739-44.
182. Hubert P, Heitzmann A, Viel S, Nicolas A, Sastre-Garau X, Oppezzo P, Pritsch O, Osinaga E, Amigorena S. Antibody-Dependent Cell Cytotoxicity Synapses Form in Mice during Tumor-Specific Antibody Immunotherapy. Cancer research. 2011; 71(15): 5134-43.
183. Welinder C, Baldetorp B, Borrebaeck C, Fredlund BM, Jansson B. A new murine IgG1 anti-Tn monoclonal antibody with in vivo anti-tumor activity. Glycobiology. 2011; 21(8): 1097-107.
184. Guadagni F, Roselli M, Cosimelli M, Spila A, Cavaliere F, Tedesco M, Arcuri R, Abbolito MR, Casale V, Pericoli MN, Vecchione A, Casciani CU, Greiner JW, Schlom J. Correlation between tumor-associated glycoprotein 72 mucin levels in tumor and serum of colorectal patients as measured by the quantitative CA 72-4 immunoassay. Cancer Res. 1996; 56(22): 5293-8.
185. Xu M, Real FX, Welt S, Schussler MH, Oettgen HF, Old LJ. Expression of TAG-72 in normal colon, transitional mucosa, and colon cancer. Int J Cancer. 1989; 44(6): 985-9.
186. Ohuchi N, Harada Y, Masuko T, Matano S, Mori S. Characterization of cell surface antigens expressed in the HMA-1 breast cancer cell line. Surg Today. 1995; 25(3): 244-50.
187. Colcher D, Pavlinkova G, Beresford G, Booth BJ, Batra SK. Single-chain antibodies in pancreatic cancer. Ann N Y Acad Sci. 1999; 880: 263-80.
188. Lastoria S, Panza N, Esposito G, Vergara E, Castelli L, Caraco C, Battista C, Pacilio G, Salvatore M. Management of patients with ovarian cancer using monoclonal antibodies. Biomed Pharmacother. 1992; 46(10): 453-63.
189. Filella X, Molina R, Jo J, Bedini JL, Joseph J, Ballesta AM. Tumor associated glycoprotein-72 (TAG-72) levels in patients with non-malignant and malignant disease. Bull Cancer. 1992; 79(3): 271-7.
190. Ikeda Y, Mori M, Kamakura T, Saku M, Sugimachi K. Immunohistochemical expression of sialyl Tn and sialyl Lewis(a) antigens in stromal tissue correlates with peritoneal dissemination in stage IV human gastric cancer. Eur J Surg Oncol. 1995; 21(2): 168-75.
191. Reddish MA, Jackson L, Koganty RR, Qiu D, Hong W, Longenecker BM. Specificities of anti-sialyl-Tn and anti-Tn monoclonal antibodies generated using novel clustered synthetic glycopeptide epitopes. Glycoconj J. 1997; 14(5): 549-60.
192. Roberge M, Estabrook M, Basler J, Chin R, Gualfetti P, Liu A, Wong SB, Rashid MH, Graycar T, Babe L, Schellenberger V. Construction and optimization of a CC49-based scFv-beta-lactamase fusion protein for ADEPT. Protein Eng Des Sel. 2006; 19(4): 141-5.
193. Agnese DM, Abdessalam SF, Burak WE, Jr., Arnold MW, Soble D, Hinkle GH, Young D, Khazaeli MB, Martin EW, Jr. Pilot study using a humanized CC49 monoclonal antibody (HuCC49DeltaCH2) to localize recurrent colorectal carcinoma. Ann Surg Oncol. 2004; 11(2): 197-202.
194. Rogers BE, Roberson PL, Shen S, Khazaeli MB, Carpenter M, Yokoyama S, Brechbiel MW, LoBuglio AF, Buchsbaum DJ. Intraperitoneal radioimmunotherapy with a humanized anti-TAG-72 (CC49) antibody with a deleted CH2 region. Cancer Biother Radiopharm. 2005; 20(5): 502-13.
195. Fang L, Holford NH, Hinkle G, Cao X, Xiao JJ, Bloomston M, Gibbs S, Saif OH, Dalton JT, Chan KK, Schlom J, Martin EW, Jr., Sun D. Population pharmacokinetics of humanized monoclonal antibody HuCC49deltaCH2 and murine antibody CC49 in colorectal cancer patients. J Clin Pharmacol. 2007; 47(2): 227-37.
196. Yu Y, Fang L, Sun D. Biodistribution of HuCC49DeltaCH2- beta-galactosidase in colorectal cancer xenograft model. Int J Pharm. 2010; 386(1-2): 208-15. PMCID: 2815147.
197. Shen S, Forero A, Meredith RF, LoBuglio AF. Biodistribution and dosimetry of In-111/Y-90-HuCC49DeltaCh2 (IDEC-159) in patients with metastatic colorectal adenocarcinoma. Cancer Biother Radiopharm. 2011; 26(1): 127-33.
198. Springer GF, Desai PR, Tegtmeyer H, Spencer BD, Scanlon EF. Pancarcinoma T/Tn antigen detects human carcinoma long before biopsy does and its vaccine prevents breast carcinoma recurrence. Ann N Y Acad Sci. 1993; 690: 355-7.
199. Sabbatini PJ, Ragupathi G, Hood C, Aghajanian CA, Juretzka M, Iasonos A, Hensley ML, Spassova MK, Ouerfelli O, Spriggs DR, Tew WP, Konner J, Clausen H, Abu Rustum N, Dansihefsky SJ, Livingston PO. Pilot study of a heptavalent vaccine-keyhole limpet hemocyanin conjugate plus QS21 in patients with epithelial ovarian, fallopian tube, or peritoneal cancer. Clin Cancer Res. 2007; 13(14): 4170-7.
200. Slovin SF, Ragupathi G, Fernandez C, Diani M, Jefferson MP, Wilton A, Kelly WK, Morris M, Solit D, Clausen H, Livingston P, Scher HI. A polyvalent vaccine for high-risk prostate patients: "are more antigens better?". Cancer Immunol Immunother. 2007; 56(12): 1921-30.
201. Slovin SF, Ragupathi G, Musselli C, Olkiewicz K, Verbel D, Kuduk SD, Schwarz JB, Sames D, Danishefsky S, Livingston PO, Scher HI. Fully synthetic carbohydratebased vaccines in biochemically relapsed prostate cancer: clinical trial results with alpha-N-acetylgalactosamine-Oserine/threonine conjugate vaccine. J Clin Oncol. 2003; 21(23): 4292-8.
202. Bolscher JG, Brevoord J, Nazmi K, Ju T, Veerman EC, van Wijk JA, Cummings RD, van Die I. Solid-phase synthesis of a pentavalent GalNAc-containing glycopeptide (Tn antigen) representing the nephropathy-associated IgA hinge region. Carbohydr Res. 2010; 345(14): 1998-2003. PMCID: 2940223.
203. Abdel-Aal AB, El-Naggar D, Zaman M, Batzloff M, Toth I. Design of fully synthetic, self-adjuvanting vaccine incorporating the tumor-associated carbohydrate Tn antigen and lipoamino acid-based Toll-like receptor 2 ligand. J Med Chem. 2012; 55(15): 6968-74.
204. Freire T, Lo-Man R, Bay S, Leclerc C. Tn glycosylation of the MUC6 protein modulates its immunogenicity and promotes the induction of Th17-biased T cell responses. J Biol Chem. 2011; 286(10): 7797-811. PMCID: 3048667.
205. Huang ZH, Shi L, Ma JW, Sun ZY, Cai H, Chen YX, Zhao YF, Li YM. A totally synthetic, self-assembling, adjuvantfree MUC1 glycopeptide vaccine for cancer therapy. J Am Chem Soc. 2012; 134(21): 8730-3.
206. Brooks CL, Schietinger A, Borisova SN, Kufer P, Okon M, Hirama T, Mackenzie CR, Wang LX, Schreiber H, Evans SV. Antibody recognition of a unique tumor-specific glycopeptide antigen. Proc Natl Acad Sci U S A. 2010; 107(22): 10056-61. PMCID: 2890472.
207. Lakshminarayanan V, Thompson P, Wolfert MA, Buskas T, Bradley JM, Pathangey LB, Madsen CS, Cohen PA, Gendler SJ, Boons GJ. Immune recognition of tumor-associated mucin MUC1 is achieved by a fully synthetic aberrantly glycosylated MUC1 tripartite vaccine. Proc Natl Acad Sci U S A. 2012; 109(1): 261-6. PMCID: 3252914.